secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kymera Therapeutics, Inc. (KYMR)
CIK:        0001815442
Form:       8-K
Filed at:   2023-05-22T23:59:59+00:00
Accession:  0001193125-23-150555
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kymera appoints Jeremy Chadwick as COO; base salary $480K, equity grants
------------------------------------------------------------------------

- Jeremy Chadwick, Ph.D., appointed COO effective May 22, 2023; previously SVP at Takeda.
- Chadwick receives $480,000 annual base salary, target bonus 40% of base, plus benefits.
- Chadwick granted option for 200,000 shares (4-year vest) and RSUs for 33,333 shares (annual vest).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815442/000119312523150555/0001193125-23-150555-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815442/000119312523150555/d434201d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-150555

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer